ATE218872T1 - Verfahren zur erhöhung der therapeutischen wirkung von nsaids und dazu verwendbare zwitterionische phospholipidhaltige zusammensetungen - Google Patents

Verfahren zur erhöhung der therapeutischen wirkung von nsaids und dazu verwendbare zwitterionische phospholipidhaltige zusammensetungen

Info

Publication number
ATE218872T1
ATE218872T1 AT96902157T AT96902157T ATE218872T1 AT E218872 T1 ATE218872 T1 AT E218872T1 AT 96902157 T AT96902157 T AT 96902157T AT 96902157 T AT96902157 T AT 96902157T AT E218872 T1 ATE218872 T1 AT E218872T1
Authority
AT
Austria
Prior art keywords
thereach
nsaids
increasing
therapeutic effect
zwitterionic
Prior art date
Application number
AT96902157T
Other languages
English (en)
Inventor
Lenard M Lichtenberger
Bruce D Butler
Original Assignee
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/440,417 external-priority patent/US5763422A/en
Application filed by Univ Texas filed Critical Univ Texas
Application granted granted Critical
Publication of ATE218872T1 publication Critical patent/ATE218872T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A61K47/544—Phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
AT96902157T 1995-01-27 1996-01-24 Verfahren zur erhöhung der therapeutischen wirkung von nsaids und dazu verwendbare zwitterionische phospholipidhaltige zusammensetungen ATE218872T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37969595A 1995-01-27 1995-01-27
US08/440,417 US5763422A (en) 1995-01-27 1995-05-12 Methods of enhancing the therapeutic activity of NSAIDS and compositions of zwitterionic phospholipids useful therein
PCT/US1996/000633 WO1996022780A1 (en) 1995-01-27 1996-01-24 Methods of enhancing the therapeutic activity of nsaids and compositions of zwitterionic phospholipids useful therein

Publications (1)

Publication Number Publication Date
ATE218872T1 true ATE218872T1 (de) 2002-06-15

Family

ID=27008731

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96902157T ATE218872T1 (de) 1995-01-27 1996-01-24 Verfahren zur erhöhung der therapeutischen wirkung von nsaids und dazu verwendbare zwitterionische phospholipidhaltige zusammensetungen

Country Status (5)

Country Link
EP (2) EP1214940B1 (de)
AT (1) ATE218872T1 (de)
DE (1) DE69621773T2 (de)
ES (1) ES2176435T3 (de)
WO (1) WO1996022780A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL127143A0 (en) 1998-11-19 1999-09-22 Dpharm Ltd Phospholipid terivatives of non-steroidal anti inflammatory drugs
IL156361A0 (en) * 2000-12-19 2004-01-04 Univ Texas Method and compositions employing formulations of lecithin oils and nsaids for protecting the gastrointestinal tract and providing enhanced therapeutic activity
US20040077604A1 (en) 2001-12-19 2004-04-22 Lenard Lichtenberger Method and compositions employing formulations of lecithin oils and nsaids for protecting the gastrointestinal tract and providingenhanced therapeutic activity
US8206741B2 (en) 2001-06-01 2012-06-26 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
CA2534241C (en) 2003-07-31 2012-05-29 The Board Of Regents Of The University Of Texas System Compositions and methods for treating, preventing and/or ameliorating cancers, the onset of cancers or the symptoms of cancers
BRPI0918492A2 (pt) 2008-09-09 2015-12-01 Astrazeneca Ab uso de naproxen, ou sal farmaceuticamente aceitável do mesmo, e esomeprazol, ou sal farmaceuticamente aceitável do mesmo
EP2445499A4 (de) 2009-06-25 2013-02-27 Astrazeneca Ab Verfahren zur behandlung eines patienten mit risiko der entwicklung eines nsaid-assoziierten geschwürs
US9730884B2 (en) 2011-09-29 2017-08-15 Plx Opco Inc. pH dependent carriers for targeted release of pharmaceuticals along the gastrointestinal tract, compositions therefrom, and making and using same
CA2860231A1 (en) 2011-12-28 2013-07-04 Pozen Inc. Improved compositions and methods for delivery of omeprazole plus acetylsalicylic acid
US20130281405A1 (en) * 2012-04-02 2013-10-24 Lenard M. Lichtenberger Use of pc-nsaids to treat and/or prevent pulmonary inflammation
CN115666523A (zh) 2020-03-26 2023-01-31 Plx 奥普科有限公司 能够进行pH依赖性重构的药物载体及其制备和使用方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4369182A (en) * 1978-09-27 1983-01-18 A. Nattermann & Cie Gmbh Inflammation-preventing pharmaceutical composition of oral administration
US4421747A (en) * 1978-12-27 1983-12-20 A. Nattermann & Cie. Gmbh Inflammation-preventing pharmaceutical composition of oral administration
DE2914788A1 (de) * 1979-04-11 1980-10-16 Nattermann A & Cie Parenteral applizierbare, stabile arzneimittelloesungen mit entzuendungshemmender wirkung
DE2914789A1 (de) * 1979-04-11 1980-10-16 Nattermann A & Cie Injizierbare arzneimittel mit entzuendungshemmender wirkung
DE2951142C2 (de) * 1979-12-19 1983-11-03 A. Nattermann & Cie GmbH, 5000 Köln Suppositorium-Zubereitung von Indometacin oder Acemetacin
JP2844756B2 (ja) * 1989-12-01 1999-01-06 日本新薬株式会社 脂肪乳剤
JP3280071B2 (ja) * 1992-05-27 2002-04-30 ポーラ化成工業株式会社 消炎鎮痛外用剤

Also Published As

Publication number Publication date
EP1214940B1 (de) 2009-03-11
DE69621773T2 (de) 2003-01-02
DE69621773D1 (de) 2002-07-18
ES2176435T3 (es) 2002-12-01
EP0805684A4 (de) 1998-08-05
EP0805684A2 (de) 1997-11-12
EP1214940A1 (de) 2002-06-19
WO1996022780A1 (en) 1996-08-01
EP0805684B1 (de) 2002-06-12

Similar Documents

Publication Publication Date Title
DE69637866D1 (de) Methoden zur Erhöhung der Wirksamkeit von nicht-steroidalen antientzündlichen Arzneien und dazu verwendbare Zusammensetzungen enthaltend zwitterionische Phospholipide
FI971776A0 (fi) Yhdisteet ja koostumukset aktiivisten aineiden antamiseksi
MX9306239A (es) Composicion farmaceutica que forma un gel de lecitina in vivo para la liberacion mantenida de un compuesto biologicamente activo y procedimiento para la preparacion de la misma.
DE69435086D1 (de) Phenylacetate und Derivate, allein oder in Kombination mit anderen Verbindungen, zur Behandlung von neoplastischen und anderen Erkrankungen
FI973828A0 (fi) Yhdisteitä ja koostumuksia aktiivisten aineiden annostelemiseksi
DE69621012D1 (de) VERWENDUNG VON NSAIDs ZUR BEHANDLUNG VON PLATTENEPITHELKARZINOM DER MUNDHÖHLE UND KEHLKOPF
DE60126980D1 (de) Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
CA2431606A1 (en) Method and compositions employing formulations of lecithin oils and nsaids for protecting the gastrointestinal tract and providing enhanced therapeutic activity
ATE218872T1 (de) Verfahren zur erhöhung der therapeutischen wirkung von nsaids und dazu verwendbare zwitterionische phospholipidhaltige zusammensetungen
ATE302588T1 (de) Dentales produkt gegen zahnstein und betreffende methode
EE200100010A (et) Kinoliini derivaadid, nende kasutamine ravimina, neid sisaldavad farmatseutilised kompositsioonid ning ühendite ja farmatseutiliste kompositsioonide kasutamine patoloogilisest põletikust ja autoimmuunsusest tingitud haiguste ravis
ATE209908T1 (de) RADIKALFÄNGER (ßSPIN TRAPSß) ZUR BEHANDLUNG VON MIT OXIDATION VON LIPIDEN UND PROTEINEN VERBUNDENEN ERKRANKUNGEN
DK0902789T3 (da) Androstenderivater
EE200100007A (et) Kinoliini derivaadid, nende kasutamine ravimina, neid sisaldavad farmatseutilised kompositsioonid ning ühendite ja farmatseutiliste kompositsioonide kasutamine patoloogilisest põletikust ja autoimmuunsusest tingitud haiguste ravis
ATE170077T1 (de) Verfahren zur behandlung von krebs durch kombinationstherapie mit 2'- halomethylidenderivaten und einem s- oder m-phase spezifischen antineoplastischen wirkstoff
IT1187687B (it) Composizioni farmaceutiche contenenti come principi attivi flavanolignani e fosfolipidi
ATE209504T1 (de) Pharmazeutische zusammensetzungen enthaltent ein superoxyddismutase
BR0010808A (pt) Composições farmacêuticas e usos
ATE223204T1 (de) Liposomenzusammensetzung
NO20012944L (no) Fosfolipidkomplekser av proantocyanidin A2 som anti- aterosklerotiske midler
ITMI922742A0 (it) Composti ad attivita' terapeutica utili per il trattamento di malattieconnesse ad una carenza di glutatione, procedimento per la loro preparazione e composizioni farmaceutiche che li contengono.
ATE548048T1 (de) Oncomodulin zur behandlung von neurologishen erkrankungen
DE69815277D1 (de) Nimelulide enthaltendes pharmazeutisches präparat zur oralen verabreichung
JO1917B1 (en) A different method for controlling high levels of bilirubin in the blood in newborns
DE60040856D1 (de) Lactalbumin zur kurativen Behandlung von Magengeschwüren

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties